ISB News

How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

Cristina Puig Saus, PhD, who led the work, and co-authors Antoni Ribas, PhD, and Jim Heath, PhD, sat down to discuss the work and its future implications. You can watch that video here, or by playing the video at the top of this page.

For more information about the Nature paper, you can read the UCLA Health story here.

 

Recent Articles

  • Spotlight on ISB Education graphic

    2023-24 School Year ISB Education Highlights

    Each month throughout the 2023-2024 academic year, we will highlight some of the top projects the ISB Education team is working on. In March, ISB Education highlights include a paper published in a Nature Portfolio journal, two events for science/STEM leaders, and more.

  • STEM Program Models for Students from Historically Marginalized Communities

    A new study unveils important insights and actionable protocols into providing equitable STEM experiences for high school students from historically marginalized communities. The research highlights the transformative power of informal STEM learning and the ease with which many organizations could provide these opportunities.

  • Common Immune Response Protective Across Many Diseases

    Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.